[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"South Valley University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":581},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,42,67,94,121,150,173,192,212,237,262,283,303,329,350,369,389,411,428,446,473,495,514,539,560],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100644879","inducible-co-stimulator-gene-with-systemic-lupus-erythematosus-100644879",false,"NCT07675837","Inducible Co-stimulator Gene With Systemic Lupus Erythematosus","Association of ICOS Gene Polymorphism With Susceptibility and Severity of Systemic Lupus Erythematosus.","ICOS\u002FSLE","Inclusion Criteria:\n\n* Patients diagnosed with SLE based on 2019 EULAR\u002FACR Male or female. willing to provide written informed consent for participation and genetic testing\n\nExclusion Criteria:\n\n* Other autoimmune diseases or chronic inflammatory disorders. Malignancy. Pregnancy or breastfeeding. Inability to provide informed consent.",true,"ALL","18 Years","65 Years",{"count":23,"type":24},30,"ESTIMATED","OBSERVATIONAL","The aim of this study is to investigate the association between ICOS gene polymorphism and susceptibility to systemic lupus erythematosus (SLE), as well as its impact on disease severity.",[28],"Systemic Lupus Erthematosus","NOT_YET_RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":24},"2026-06",{"date":37,"type":24},"2027-07",{"name":39,"class":40},"South Valley University","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100644065","general-versus-spinal-anesthesia-in-rirs-100644065","NCT07664384","General Versus Spinal Anesthesia in RIRS","Comparative Study of General Versus Spinal Anesthesia in Retrograde Intrarenal Surgery: Impact of Stone Size on Perioperative Outcomes","Inclusion Criteria:\n\n* Adult patients (≥18 years) scheduled for elective RIRS for renal stones \\\u003C2 cm.\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* History of previous ureteral surgery or known ureteral stricture.\n* Multiple or bilateral renal stones requiring staged procedures.",{"count":50,"type":24},80,"The impact of anesthesia type on Retrograde Intrarenal Surgery (RIRS) outcomes remains a subject of ongoing debate. Several studies have compared general anesthesia (GA) and spinal anesthesia (SA) in endourological procedures, with conflicting results regarding operative time, complication rates, and stone-free outcomes. Importantly, the interaction between anesthesia type and stone characteristics-particularly stone size-has not been fully elucidated. Therefore, this study aims to conduct a retrospective comparative analysis of general versus spinal anesthesia in patients undergoing RIRS at Qena University Hospital, with particular emphasis on the effect of stone size stratification on perioperative outcomes.",[53],"Retrograde Intrarenal Surgery",[55,56,57,58],"RIRS","Spinal Anesthesia","General Anesthesia","Perioperative Outcomes","2026-06-22",{"date":61,"type":33},"2026-06-25",{"date":63,"type":24},"2026-07",{"date":65,"type":24},"2026-09",{"name":39,"class":40},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":12,"sex":19,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":41},"100615777","naples-prognostic-score-for-predicting-postoperative-delirium-100615777","NCT07297017","Naples Prognostic Score for Predicting Postoperative Delirium","Naples Prognostic Score for Predicting Postoperative Delirium in the Elderly Undergoing Hip Fracture Surgeries","Inclusion Criteria:\n\n* The elderly age≥60 years\n* American Society of Anesthesiologists (ASA) classification II∼IV\n* Patients undergoing hip fracture surgery\n* Patients who had a complete blood sample were taken preoperatively\n\nExclusion Criteria:\n\n* Patient refused to participate and consent\n* Patients with a history of mild cognitive impairment (MCI), dementia, and delirium\n* Ptients with known preoperative infections (pulmonary infection, urinary infection, and sepsis).","60 Years",{"count":76,"type":24},168,"Naples Prognostic Score (NPS) originally developed to predict outcomes in inflammatory and malignant conditions; we asked if it can effectively predict postoperative delirium (POD) in elderly patients undergoing hip surgery? NPS integrate markers such as albumin, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio-all of which have been linked to adverse postoperative outcomes including POD.",[79],"Postoperative Delirium",[81,82,83,84],"POD","elderly","geriatric","NPS","RECRUITING","2026-05-13",{"date":88,"type":33},"2026-05-14",{"date":90,"type":33},"2026-01-10",{"date":92,"type":24},"2027-12",{"name":39,"class":40},{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":18,"sex":19,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100634331","biomechanical-muscle-properties-and-balance-in-children-with-spastic-hemiplegia-100634331","NCT07538297","Biomechanical Muscle Properties and Balance in Children With Spastic Hemiplegia","Muscle Biomechanical Properties and Postural Control During Static and Dynamic Standing in Children With Spastic Hemiplegia","BMPB-HCP","Inclusion Criteria:\n\n* Their age will range from 6 to 12 years.\n* Mild degree of spasticity ranged from 1 to 1+ according to Modified Ashworth Scale\n* Their motor function will be at level I and II according to Gross Motor Function Classification System GMFCS\n* They will be able to follow instructions during evaluation procedures.\n* Their caregivers are of a good command of the English language.\n\nExclusion Criteria:\n\n* Botulinum toxin injections in the last 6 months.\n* The presence of visual or auditory impairments.\n* Surgical interference in upper, lower limbs and\u002For spine.\n* Muscloskeletal problems or fixed deformities in the spine and\u002For upper or\u002Fand lower extremities.\n* Seizures.","6 Years","12 Years",{"count":105,"type":24},40,"this study will be conducted to investigate the relationship between muscle tone and dynamic stiffness during balance control and postural stability in children with spastic hemiplegia",[108],"Spastic Hemiplegia",[110,111,112],"biomechanical Properties","balance","spastic hemiplegia","2026-04-12",{"date":115,"type":33},"2026-04-20",{"date":117,"type":24},"2026-04-17",{"date":119,"type":24},"2026-07-01",{"name":39,"class":40},{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":18,"sex":128,"minAge":129,"maxAge":21,"enrollmentInfo":130,"targetDuration":4,"studyType":132,"phases":133,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":41},"100629749","shoulder-exercise-training-on-pain-range-of-motion-and-functional-limitations-in-women-following-unilateral-mastectomy-100629749","NCT07478718","Shoulder Exercise Training on Pain, Range of Motion, and Functional Limitations in Women Following Unilateral Mastectomy","Effect of Targeted Scapular and Shoulder Exercise Training on Pain, Range of Motion, and Functional Limitations in Women Following Unilateral Mastectomy \"Randomized Controlled Trial\"","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\n  1. Female adults between 30 and 65 years old.\n  2. History of unilateral breast cancer managed with either:\n\n     * Modified radical mastectomy, or\n     * Breast-conserving surgery with axillary clearance.\n  3. Postoperative interval between 4 and 12 weeks before enrollment.\n  4. Objective evidence of impaired shoulder mobility or function including:\n\n     * Reduction of ROM ≥ 15% compared to the contralateral side,\n     * VAS pain ≥ 3\u002F10 during shoulder movement, or\n     * DASH functional score \\> 25.\n  5. Ability to ambulate independently and follow therapist instructions.\n  6. Willingness to commit to the full rehabilitation protocol for 8 weeks.\n\nExclusion Criteria:\n\n* Participants will be excluded if they have:\n\n  * Previously diagnosed shoulder disorders (adhesive capsulitis, rotator cuff tear, fracture\u002Fdislocation).\n  * Active or untreated lymphedema Grade II-III.\n  * Ongoing chemotherapy-induced neuropathy causing shoulder dysfunction.\n  * History of neurological or rheumatological disorders affecting the upper limb.\n  * Metastatic disease or local recurrence.\n  * Recent infection, seroma, or unhealed surgical wounds.\n  * Participation in another physical therapy or exercise program in the past 4 weeks.\n  * Cognitive impairment or psychiatric conditions interfering with adherence.","FEMALE","30 Years",{"count":131,"type":24},33,"INTERVENTIONAL",[134],"NA","Shoulder pain, reduced mobility, and functional limitations are common complications following unilateral mastectomy, often leading to long-term disability and an increased risk of secondary shoulder-hand syndrome",[137],"Women Following Unilateral Mastectomy",[139,140,141,137],"Breast cancer","Shoulder rehabilitation","Scapular exercises","2026-03-17",{"date":144,"type":33},"2026-03-20",{"date":146,"type":24},"2026-04-01",{"date":148,"type":24},"2026-08-01",{"name":39,"class":40},{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":18,"sex":128,"minAge":20,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":41},"100625523","ultrasonographical-assessment-of-airway-indices-in-pregnancy-100625523","NCT07423741","Ultrasonographical Assessment of Airway Indices in Pregnancy","Clinical and Ultrasonographic Assessment of Airway Indices Among Nonpregnant, Normotensive Pregnant and Pre-eclamptic Patients: a Prospective Observational Study","Inclusion Criteria:\n\n* -normotensive pregnant\n* pre-eclamptic patients.\n* nonpregnant females in child bearing period .\n\nExclusion Criteria:\n\n* Patients excluded were women at \\\u003C32 weeks' gestation or with Eclampsia .\n* height \\\u003C150 cm, body mass index (BMI) \\>30 kg\u002Fm2 .\n* predicted airwy difficulty due to any other cause as neck swelling , facial deformity and prominent teeth.","50 Years",{"count":159,"type":24},180,"Clinical and ultrasound indices of airway, in addition to laryngoscopic view will be assessed and compared among three groups of patients: non pregnant, pregnant with normal blood pressure, preeclampsia patients undergoing various surgeries under general anesthesia.",[162],"Airway Assessment",[164],"airway, ultrasound, preeclampsia","2026-02-17",{"date":167,"type":33},"2026-02-20",{"date":169,"type":33},"2024-12-15",{"date":171,"type":24},"2026-12",{"name":39,"class":40},{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":19,"minAge":74,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":132,"phases":182,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":191,"locationsCount":41},"100613616","femoral-rami-obturator-nerve-trunk-front-block-in-intramedullary-nail-surgery--100613616","NCT07268911","Femoral Rami Obturator Nerve Trunk (FRONT) Block in Intramedullary Nail Surgery .","FRONT block","Inclusion Criteria:\n\n* the elderly age≥60 years\n* American Society of Anesthesiologists (ASA) classification 1-2\n* patients who undergoing surgery for intramedullary nail surgery.\n\nExclusion Criteria:\n\n* patient refused to participate and consent\n* patients with a history of mild cognitive impairment (MCI), dementia, and delirium\n* patients with known preoperative infections (pulmonary infection, urinary infection, and sepsis).\n* coagulopathy",{"count":181,"type":24},60,[134],"The study propose that using femoral rami obturator nerve trunk(FRONT) block may help postoperative analgesia in nail femur surgeries. The technique is relatively new, introducing one needle to target two nerve blocks in the same entry point. The block spare motor fibers of femoral nerve so it may help both early mobilization and effective analgesia, which in turn enhance early recovery and better outcomes.",[185],"Anterior Hip Analgesia",{"date":187,"type":33},"2026-02-19",{"date":189,"type":33},"2025-11-01",{"date":35,"type":24},{"name":39,"class":40},{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":74,"enrollmentInfo":199,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":41},"100623522","trex1-gene-mutations-and-their-role-in-systemic-lupus-erythematosus-100623522","NCT07397728","\" TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus","TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus: A Genotype-Phenotype Correlation Study","Inclusion Criteria:\n\n* Adult aged 18-60 years\n* Diagnosed as SLE per 2019 EULAR\u002FACR classification criteria.\n* Presence of at least one cutaneous manifestation (acute, subacute, or chronic).\n* Willing to provide written informed consent for participation and genetic testing\n\nExclusion Criteria:\n\n* Overlap autoimmune syndromes (e.g., dermatomyositis, systemic sclerosis).\n* Systemic infection, malignancy, or pregnancy.\n* Use of biologic therapy or immunosuppressive pulses within one month.",{"count":200,"type":24},90,"Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by diverse clinical manifestations, prominently involving the skin.",[203],"Systemic Lupus Erythematosus","2026-02-05",{"date":206,"type":33},"2026-02-09",{"date":208,"type":33},"2025-06-10",{"date":210,"type":24},"2026-06-10",{"name":39,"class":40},{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":19,"minAge":219,"maxAge":157,"enrollmentInfo":220,"targetDuration":4,"studyType":132,"phases":221,"briefSummary":222,"conditions":223,"keywords":226,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":41},"100613328","gait-training-and-artificial-intelligence-100613328","NCT07265154","Gait Training and Artificial Intelligence","Gait Training in Above Knee Amputation Patients Using Artificial Intelligence","Inclusion Criteria:\n\n* All patients have above-knee amputations.\n* All patients have no other neurological diseases affecting gait.\n* All patients have no other neurological diseases affecting muscle balance.\n* All patients have no other complications affecting joint ROM.\n\nExclusion Criteria:\n\n* Patients have any complications affecting joint ROM.\n* Patients have any neurological condition affecting muscle balance.\n* Patients have any neurological condition affecting gait.","16 Years",{"count":105,"type":24},[134],"Effect of Using Artificial Intelligence on Gait Training in Above Knee Amputation Patients",[224,225],"Above Knee Amputation","Amputation",[225,224,227,228],"Artificial Intelligence","Gait training","2025-11-23",{"date":231,"type":33},"2025-12-04",{"date":233,"type":24},"2025-12-01",{"date":235,"type":24},"2026-03-01",{"name":39,"class":40},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":19,"minAge":243,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":132,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":41},"100608733","phase-one-cardiac-rehabilitation-outcomes-post-valve-replacement-surgery-100608733","NCT07205393","Phase One Cardiac Rehabilitation Outcomes Post Valve Replacement Surgery","Inclusion Criteria:\n\n* The inclusion criteria was elective mitral or aortic valve replacement\n* and to be hemodynamically stable to qualify for a structured rehabilitation program.\n* Being able to understand and complete measurements.\n* And provide informed written consent.\n\nExclusion Criteria:\n\n* Patient with ischemic heart disease before surgery.\n* Those with severe musculoskeletal system disorders.\n* Patients who had persistent or paroxysmal atrial fibrillation.\n* Individuals with severe heart failure.\n* uncontrolled arrhythmias.\n* Comorbidity complicating physical activity or other contraindications to phase one cardiac rehabilitation and Patients who underwent an emergency surgical intervention.","40 Years","55 Years",{"count":181,"type":24},[134],"Cardiac rehabilitation is a crucial component of postoperative recovery for patients who have received valve replacement surgery. Aim: This study aimed to evaluate the effectiveness of phase one cardiac rehabilitation in improving cardiovascular function, pulmonary capacity, functional ability, and quality of life.",[249],"Valve Replacement Surgery",[251,252,253],"Cardiac rehabilitation","Valve replacement","Spirometry measures","2025-09-30",{"date":256,"type":33},"2025-10-03",{"date":258,"type":33},"2025-01-01",{"date":260,"type":24},"2025-10-20",{"name":39,"class":40},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":269,"enrollmentInfo":270,"targetDuration":4,"studyType":132,"phases":271,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":41},"100602819","evaluation-of-il-12b-genetic-polymorphism-rs3213094-100602819","NCT07128472","Evaluation of IL 12B Genetic Polymorphism (rs3213094)","Evaluation of IL 12B Genetic Polymorphism (rs3213094) in Patient With Psoriasis and Psoriatic Arthritis in Response to Humira","Inclusion Criteria:\n\n\\- Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater than 10% of the body surface area (BSA) with psoriatic arthritis.\n\nExclusion Criteria:\n\n* Patients with other autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, lupus).\n* Pregnancy and lactation.\n* Patients currently undergoing any treatment other than Humira.\n* Patients with known genetic disorders affect immune system function.\n* Patients were undergoing any treatment other than Humira in the last 6 months.\n* Patients with active infections, including tuberculosis or chronic viral infections (e.g., hepatitis B or C, HIV).\n* Patients with contraindication to Humira.\n* Renal \\&Vascular diseases","70 Years",{"count":105,"type":24},[134],"Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales. The disease can also impair the eyes and joints. It has no cure. Because of their low quality of life, many psoriasis patients experience depression. In addition to the cutaneous manifestations, it is associated with an increased risk of psoriatic arthritis, depression and cardiovascular disease.",[274],"Psoriasis","2025-08-13",{"date":277,"type":33},"2025-08-19",{"date":279,"type":33},"2025-08-01",{"date":281,"type":24},"2026-02-01",{"name":39,"class":40},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":269,"enrollmentInfo":290,"targetDuration":4,"studyType":132,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":302,"locationsCount":41},"100599625","genetic-variation-in-traf3ip2-rs13190932-100599625","NCT07086924","Genetic Variation in TRAF3IP2 (rs13190932)","Genetic Variation in TRAF3IP2 (rs13190932) and Its Association With Psoriasis, Psoriatic Arthritis, and Treatment Outcome With Methotrexate","Inclusion Criteria:\n\n* Patients aged 18 -70years .\n* the severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI \\> 12 (severe severity). (15)Confirmed diagnosis: Psoriasis vulgaris (PsV) or psoriatic arthritis (PsA) diagnosed by the Dermatologist or the Rheumatologist.\n* Willingness to participate: Signed informed consent.\n* Initiating methotrexate (MTX) therapy: For prospective cohort.\n* Availability for follow-up: Patients must be willing and able to attend scheduled visit.\n\nExclusion Criteria:\n\n* Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus).\n* Pregnancy and lactation.\n* Patients currently undergoing immunosuppressive or systemic therapies.\n* Patients with known genetic disorders affect immune system function.\n* Patients with liver or kidney impairment.\n* Patients with allergy or contraindication to methotrexate.\n* Patients with active or uncontrolled infections, including chronic infections like tuberculosis.\n* Previous genetic analysis Patients who have previously undergone genetic analysis for the TRAF3IP2 gene polymorphism (rs13190932).",{"count":291,"type":24},50,[134],"Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population.\n\nIt is characterized by red, scaly plaques that can appear on various parts of the body, causing significant physical and psychological burden to affected individuals.\n\nThe Pathogenesis of PsA involves a complex interplay of genetic, immunological, and environmental factors.Genetic studies have identified several susceptibility loci, including HLA-Cw6 and IL23R, which are shared with psoriasis. Additionally, the presence of certain alleles, such as HLA-B27, is associated with a more severe disease course and a higher likelihood of axial involvement.",[274,295],"Psoriatic Arthritis","2025-07-18",{"date":298,"type":33},"2025-07-25",{"date":300,"type":33},"2025-06-01",{"date":210,"type":24},{"name":39,"class":40},{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":18,"sex":19,"minAge":243,"maxAge":269,"enrollmentInfo":310,"targetDuration":4,"studyType":132,"phases":312,"briefSummary":313,"conditions":314,"keywords":317,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":326,"leadSponsor":328,"locationsCount":4},"100598365","effect-of-electromagnetic-field-therapy-and-customized-foot-insole-on-peripheral-circulation-and-ankle-brachial-pressure-index-in-patients-with-diabetic-foot-ulcer-100598365","NCT07070544","Effect of Electromagnetic Field Therapy and Customized Foot Insole on Peripheral Circulation and Ankle-Brachial Pressure Index in Patients With Diabetic Foot Ulcer","Head of Department of Physical Therapy for Cardiovascular\u002FRespiratory Disorders and Geriatrics","Inclusion Criteria:\n\n* • Diagnosed with Type 2 Diabetes Mellitus.\n\n  * Presence of unilateral or bilateral diabetic foot ulcer.\n  * ABPI between 0.6 - 1.0 (mild to moderate arterial insufficiency).\n\nExclusion Criteria:\n\n* • Severe peripheral arterial disease (ABPI \\\u003C0.5).\n\n  * Active infection requiring hospitalization.\n  * History of amputation.\n  * Cardiac pacemaker or contraindication to EMF therapy.",{"count":311,"type":24},79,[134],"Diabetic foot ulcers (DFUs) are a significant complication of diabetes mellitus, associated with poor peripheral circulation, neuropathy, and increased risk of lower-limb amputation. Optimizing peripheral blood flow is critical in the prevention and management of DFUs. Traditional offloading strategies, such as customized foot insoles, have demonstrated efficacy in reducing plantar pressure and promoting ulcer healing.\n\nElectromagnetic field (EMF) therapy is a non-invasive modality that has shown potential in enhancing microcirculation, promoting angiogenesis, and modulating inflammatory processes. Preliminary studies have suggested that EMF may improve peripheral circulation and tissue oxygenation in diabetic patients.\n\nThis study aims to investigate the combined effect of EMF therapy and customized foot insoles on peripheral circulation and Ankle-Brachial Pressure Index (ABPI) in patients with diabetic foot ulcers, hypothesizing that this integrated approach may yield superior outcomes compared to standard care.",[315,316],"Diabetes Mellitus","Diabetic Foot Ulcer",[318,319,320,321],"Effect of Electromagnetic Field Therapy","Customized Foot Insole","Peripheral Circulation","Ankle-Brachial Pressure Index","2025-07-16",{"date":324,"type":33},"2025-07-17",{"date":279,"type":24},{"date":327,"type":24},"2026-01-01",{"name":39,"class":40},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":18,"sex":336,"minAge":20,"maxAge":74,"enrollmentInfo":337,"targetDuration":4,"studyType":132,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":41},"100597324","therapeutic-outcomes-of-selective-serotonin-reuptake-inhibitors-and-phosphodiesterase-5-inhibitors-combination-therapy-versus-monotherapy-100597324","NCT07057011","Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy","Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy in Premature Ejaculation Patients With the Serotonin Transporter Gene Polymorphism (SLC6A4)","Inclusion Criteria:\n\n* Patients with PE: Men aged 18-60 years with a diagnosis of PE according to the International Society for Sexual Medicine (ISSM) criteria.\n* Healthy controls: Men aged 18-60 years without a history of PE or other sexual dysfunctions.\n\nExclusion Criteria:\n\n* Other sexual dysfunctions: Erectile dysfunction, delayed ejaculation, or other sexual disorders.\n* Cardiovascular disease: history of cardiovascular disease, hypertension, or stroke.\n* Neurological or psychiatric disorders: Conditions that may affect sexual function, such as depression, anxiety, or Parkinson's disease.\n* Medications affecting sexual function: Current use of medications that may impact sexual function, such as antidepressants or antipsychotics.","MALE",{"count":181,"type":24},[134],"Premature ejaculation (PE) is a prevalent male sexual dysfunction that affects as many as 20-30% of men regardless of age and ethnicity.The International Society for Sexual Medicine defines premature ejaculation as a male sexual dysfunction characterised by ejaculation that always or nearly always occurs before or within about 1 minute of vaginal penetration from the first sexual experience (lifelong premature ejaculation) or a clinically significant and bothersome reduction in latency time, often to about 3 minutes or less (acquired premature ejaculation), the inability to delay ejaculation on all or nearly all vaginal penetrations and with negative personal consequences include distress, bother, frustration, and avoidance of sexual intimacy.",[341],"Premature Ejaculation","2025-07-06",{"date":344,"type":33},"2025-07-09",{"date":346,"type":24},"2025-07-01",{"date":348,"type":24},"2026-02-10",{"name":39,"class":40},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":18,"sex":128,"minAge":20,"maxAge":243,"enrollmentInfo":357,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":4},"100553939","examination-of-biomechanical-characteristics-of-linea-alba-in-diastasis-recti-patients-100553939","NCT06492603","Examination of Biomechanical Characteristics of Linea Alba in Diastasis Recti Patients","Examination of Linea Alba Biomechanical and Viscoelastic Characteristics in Patients Diagnosed With Diastasis Recti Using Ultrasound","Inclusion Criteria:\n\n* Postpartum Mothers who delivered by a cesarean section.\n* Postpartum Mothers with a BMI below 30 or a Waist-hip ratio below 1.\n* Postpartum Mothers above 18 years old and those below 40 years old.\n\nExclusion Criteria:\n\n* Postpartum Mothers who delivered by a vaginal delivery.\n* Postpartum Mothers who had hernias in the abdominal region or laparotomy.\n* Postpartum Mothers with a BMI over 30 or a Waist-hip ratio over 1.\n* Postpartum Mothers below 18 years old and those above 40 years old.",{"count":105,"type":24},"Diastasis recti is an increased distance between the rectus abdominis muscles at the midline caused by weakness in the anterior abdominal wall.",[360],"Separated Recti Abdominis","2025-06-30",{"date":363,"type":33},"2025-07-03",{"date":365,"type":24},"2025-07-20",{"date":367,"type":24},"2025-12-30",{"name":39,"class":40},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":128,"minAge":376,"maxAge":269,"enrollmentInfo":377,"targetDuration":4,"studyType":132,"phases":378,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":388,"locationsCount":41},"100596254","laparoscopic-versus-open-surgical-repair-of-genitovesical-fistula-in-females-100596254","NCT07043062","Laparoscopic Versus Open Surgical Repair of Genitovesical Fistula in Females","Laparoscopic Versus Open Surgical Repair of Genitovesical Fistula in Females :ِ A Prospective Comparative Non Randomized Study","Inclusion Criteria:\n\n* Females with Vesicovaginal fistula or Vesicouterine fistula.\n* Timing of repair after 2-6 months of beginning of symptoms and signs of fistula.\n\nExclusion Criteria:\n\n* Malignant , Recurrant or Post Radiation Genitovesical fistula.\n* Females with congenital disease in Bladder ,Uterus or Vagina.\n* Females with Vaginal or Uterine prolapse.","25 Years",{"count":291,"type":24},[134],"Fistula is an abnormal passway that connects two organs or vessels that do not connect normally.\n\nGenitourinary fistula refers to a fistula that occurs between reproductive tract organs (vagina, cervix, and uterus), and lower urinary tract (bladder, urethra, and pelvic ureters).\n\nIt is a serious condition which can significantly influence the biological and psychological condition of women, with a negative impact on the quality of life.",[381],"Genitovesical Fistula","2025-06-20",{"date":384,"type":33},"2025-06-29",{"date":386,"type":33},"2024-08-01",{"date":279,"type":24},{"name":39,"class":40},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":336,"minAge":396,"maxAge":157,"enrollmentInfo":397,"targetDuration":4,"studyType":132,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":41},"100594240","medical-treatment-alone-versus-varicocelectomy-versus-varicocelectomy-and-medical-treatment-100594240","NCT07016867","Medical Treatment Alone Versus Varicocelectomy Versus Varicocelectomy and Medical Treatment","Medical Treatment Alone Versus Varicocelectomy Versus Varicocelectomy and Medical Treatment in Management of Male Subfertility With Isolated Teratozoospermia: A Prospective Randomized Study","Inclusion Criteria:\n\n* Sub-fertile men with clinically palpable varicoceles ( unilateral or bilateral ).\n* Men with teratozoospermia.\n\nExclusion Criteria:\n\n* Recurrent varicoceles.\n* Significant medical diseases as: Hepatic insufficiency.\n* Hypersensitivity to the drugs.\n* Female factor of infertility.","20 Years",{"count":398,"type":24},126,[134],"A varicocele is defined as an abnormal venous dilatation and\u002For tortuosity of the pampiniform plexus in the scrotum. Although varicoceles are almost always and more common on the left side, up to 50% of the men with varicocele, have bilateral varicoceles.\n\nVaricocele has a negative impact on spermatogenesis, testicular volume, Standard semen parameters, and fertilization, implantation, and embryo outcomes.",[402],"Teratozoospermia","2025-06-11",{"date":405,"type":33},"2025-06-12",{"date":407,"type":33},"2024-09-01",{"date":409,"type":24},"2025-08-31",{"name":39,"class":40},{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":336,"minAge":396,"maxAge":74,"enrollmentInfo":418,"targetDuration":4,"studyType":132,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":426,"leadSponsor":427,"locationsCount":41},"100593596","testicular-sperm-retrieval-rate-after-varicocele-ligation-in-men-with-non-obstructive-azoospermia-100593596","NCT07008495","Testicular Sperm Retrieval Rate After Varicocele Ligation in Men With Non Obstructive Azoospermia","Testicular Sperm Retrieval Rate After Varicocele Ligation in Men With Non Obstructive Azoospermia.","Inclusion Criteria:\n\n* Men with non obstructive azoospermia.\n* Clinically palpable varicocele ( unilateral or bilateral ).\n\nExclusion Criteria:\n\n* Known cases of obstructive azoospermia.\n* Non palpable varicocele.\n* Uncorrectable female causes of infertility.\n* genetic abnormalities like klinefelter syndrome.",{"count":291,"type":24},[134],"A varicocele is an abnormal dilatation and tortuosity of the veins of the spermatic cord. Although varicoceles are common in the general population and are frequently found on routine physical examinations, they represent the most common correctable cause of male factor infertility.\n\nMale factor infertility affects up to half of all couples struggling to conceive, and 10-20% of men evaluated for infertility are found to be azoospermic.",[422],"Non-obstructive Azoospermia",{"date":424,"type":33},"2025-06-13",{"date":407,"type":33},{"date":409,"type":24},{"name":39,"class":40},{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":19,"minAge":219,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":444,"leadSponsor":445,"locationsCount":41},"100593620","the-facial-muscular-activity-a-paradigm-for-understanding-facial-asymmetry-100593620","NCT07008807","The Facial Muscular Activity: A Paradigm for Understanding Facial Asymmetry","The Facial Muscular Activity: A Paradigm for Understanding Facial Asymmetry, A Prospective Correlation Study","Inclusion Criteria:\n\n* Presenting with noticeable facial asymmetry\n* Age \\> 16 years\n* General good health\n* Absence of specific neurological conditions affecting facial muscles.\n* Absence of congenital facial disorders that might cause facial asymmetry, like hemifacial microsomia and cleft lip and palate syndromes.\n\nExclusion Criteria:\n\n* History of facial trauma or surgery\n* Diagnosed Neuromuscular Disorders\n* Active facial infections.",{"count":436,"type":24},100,"Facial asymmetry, the degree to which the two sides of the face differ in size, shape, or the arrangement of features, is a near-universal human characteristic. The intricate network of facial muscles plays a crucial role in both the static structure and the dynamic expressions of the face. The continuous pull and action of facial muscles can influence the development and positioning of underlying soft tissues and even, over extended periods, potentially impact skeletal structures.",[439],"Facial Asymmetry","2025-05-29",{"date":442,"type":33},"2025-06-06",{"date":300,"type":24},{"date":279,"type":24},{"name":39,"class":40},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":336,"minAge":157,"maxAge":454,"enrollmentInfo":455,"targetDuration":4,"studyType":132,"phases":456,"briefSummary":457,"conditions":458,"keywords":463,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":471,"leadSponsor":472,"locationsCount":41},"100591670","bipolar-resection-vs-enucleation-of-prostate-100591670","NCT06983444","Bipolar Resection vs Enucleation of Prostate","Bipolar Trans Urethral Resection of the Prostate (TURP) Versus Bipolar Enucleation of the Prostate in Treatment of Benign Prostatic Hyperplasia (BPH): A Prospective Randomized Comparative Clinical Study","TURP vs BiTUEP","Inclusion Criteria:\n\n1. Patients with lower urinary tract symptoms (LUTS) due to BPH.\n2. Patients with international prostate score system (IPSS) more than 8.\n3. Patients with maximal urinary flow rate (Qmax) less than 10ml\u002Fsecond.\n4. Patients with Prostatic volume (60 - 100 gm).\n5. Patient with indication for surgical intervention.\n6. Patient age (50-80 years old)\n\nExclusion Criteria:\n\n1. Prostatic cancer.\n2. Bladder cancer.\n3. Urethral stricture.\n4. Neurogenic bladder.","80 Years",{"count":436,"type":24},[134],"The aim of this study is to evaluate efficacy and safety of transurethral resection of the prostate and bipolar enucleation of the prostate.",[459,460,461,462],"Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection","Benign Prostatic Hyperplasia With Outflow Obstruction","Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms","Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms",[464,465,466],"TURP","TUEP","BPH","2025-05-17",{"date":469,"type":33},"2025-05-21",{"date":300,"type":24},{"date":63,"type":24},{"name":39,"class":40},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":18,"sex":336,"minAge":129,"maxAge":74,"enrollmentInfo":480,"targetDuration":4,"studyType":132,"phases":481,"briefSummary":482,"conditions":483,"keywords":485,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":4},"100590057","daily-tadalafil-in-diabetic-ed-patients-100590057","NCT06962462","Daily Tadalafil in Diabetic ED Patients","Effect of Daily Tadalafil Therapy on Endothelin-1 and E-Selectin in Diabetic Patients With Erectile Dysfunction","Inclusion Criteria:\n\nMale patients aged between 30 and 60 yearsز Diagnosed with diabetes mellitus Suffering from erectile dysfunction No history of hypertension or other systemic diseases\n\nExclusion Criteria:\n\nHistory of pelvic trauma or major pelvic surgery Pacientes con hipogonadismo o hiperprolactinemia Chronic liver disease or cardiovascular disorders Chronic use of central nervous system drugs, anti-androgenic drugs, or Tramadol Smokers Non-vasculogenic erectile dysfunction Known allergy to tadalafil",{"count":181,"type":24},[134],"This study evaluates the effect of 5 mg daily tadalafil therapy on serum levels of Endothelin-1 and E-selectin in diabetic male patients with erectile dysfunction. Outcomes will be compared pre- and post-treatment versus healthy controls.",[484],"Erectile Dysfunction Associated With Type 2 Diabetes Mellitus",[486],"Tadalafil, Endothelin-1, E-selectin, Diabetic complications, Sexual dysfunction, ELISA","2025-05-07",{"date":489,"type":33},"2025-05-08",{"date":491,"type":24},"2025-05-05",{"date":493,"type":24},"2025-08-30",{"name":39,"class":40},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":157,"enrollmentInfo":502,"targetDuration":4,"studyType":132,"phases":503,"briefSummary":504,"conditions":505,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":41},"100582990","card14gene-rs34367357--polymorphism-in-egyptian-psoriatic-and-psoriatic-arthritis-patient-100582990","NCT06870500","Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient","Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient and Its Relation With Response to Methotrexate","Inclusion Criteria:\n\n* Patients aged 18 years and above.\n* Patients having psoriasis diagnosed clinically and who have a severity grade of moderate to severe, defined as a Psoriasis Area and Severity Index (PASI) score from 5- 10 % of body surface area, and involvement of greater than 10% of the body surface area (BSA) with or without psoriatic arthritis\n\nExclusion Criteria:\n\n* Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus).\n* Pregnancy and lactation.\n* Patients currently undergoing immunosuppressive or systemic therapies.\n* Patients with known genetic disorders affect immune system function.\n* Patients with liver or kidney impairment.\n* Patients with allergy or contraindication to methotrexate.\n* Patients with active or uncontrolled infections, including chronic infections like tuberculosis.",{"count":291,"type":24},[134],"Psoriasis is a chronic, immune-mediated, multisystemic, inflammatory disease caused by the interaction of multiple susceptibility genes and environmental factors that affects 1-3% of the population worldwide .Psoriasis also is a chronic inflammatory skin disease characterized by scaly indurated erythema.\n\nPsoriatic arthritis (PsA) is an autoimmune and chronic musculoskeletal disorder that is associated with psoriasis of the skin . Its presentation can vary from subtle manifestations to highly destructive forms. Joint pain, stiffness and swelling are the most common symptoms.",[295],"2025-03-10",{"date":508,"type":33},"2025-03-11",{"date":510,"type":33},"2025-03-05",{"date":512,"type":24},"2026-03-10",{"name":39,"class":40},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":18,"sex":19,"minAge":157,"maxAge":269,"enrollmentInfo":520,"targetDuration":4,"studyType":132,"phases":521,"briefSummary":522,"conditions":523,"keywords":525,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":41},"100580293","monitoring-combined-effect-of-balance-and-strengthening-exercises-on-static-and-dynamic-balance-in-elderly-populations-100580293","NCT06835413","Monitoring Combined Effect of Balance and Strengthening Exercises on Static and Dynamic Balance in Elderly Populations","Inclusion Criteria:\n\n* geriatrics balance disturbance with high risk falling\n* osteoporosis\n* vestibular age related changes\n* female post-menopausal based on history\n\nExclusion Criteria:\n\n* Hiatus hernia\n* Substantial gastro-esophageal reflux\n* Acute cardiac events\n* Uncontrolled diabetes mellitus\n* Hypertension within the last six weeks\n* Congestive heart failure,\n* Acute exacerbation, exacerbation six months before\n* Active hemoptysis, or malignant disease",{"count":181,"type":24},[134],"The purpose of training is to evoke improvements in reactive balance, then the training program may be associated with all postural control systems, including the musculoskeletal system, the cognitive system, as well as the somatosensory feedback system, while challenging the body in different environmental situations and unexpected perturbations",[524],"Geriatrics Balance Disturbance With High Risk Falling, Osteoporosis, Vestibular Age Related Changes, Female Post-menopausal Based on History",[526,527,528,529,530],"1-Static balance","2- dynamic balance","3- Geriatrics populations","4- Balance exercises","5-Strengthening exercises","2025-02-18",{"date":533,"type":33},"2025-02-19",{"date":535,"type":24},"2025-05-15",{"date":537,"type":24},"2026-01-15",{"name":39,"class":40},{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":18,"sex":19,"minAge":157,"maxAge":74,"enrollmentInfo":546,"targetDuration":4,"studyType":132,"phases":548,"briefSummary":549,"conditions":550,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":4},"100568474","effectiveness-of-combined-manual-therapy-and-pulmonary-exercises-on-ventilatory-function-in-patients-with-restrictive-lung-diseases-100568474","NCT06681701","Effectiveness of Combined Manual Therapy and Pulmonary Exercises on Ventilatory Function in Patients with Restrictive Lung Diseases","Effectiveness of Combined Manual Therapy and Pulmonary Exercises on Ventilatory Function in Patients with Restrictive Lung Diseases: a Randomized Control Trial","Inclusion Criteria:\n\nRestrictive lung diseases pneumonia pulmonary edema pleural effusion pneumothorax\n\nExclusion Criteria:\n\nhiatus hernia substantial gastro-esophageal reflux acute cardiac events osteoporosis congestive heart failure active hemoptysis malignant disease",{"count":547,"type":24},72,[134],"This research investigates the effect of selective manual therapy techniques on chest expansion, pulmonary function (FVC, FEV1, and FEV1\u002FFVC ratio), and functional capacity, in restrictive lung disease patients. The research hypothesis will be that no statistically significant difference would be found between manual therapy combined to conventional treatment and conventional treatment alone in restrictive lung disease patients.",[551],"Study the Effectiveness of Combined Manual Therapy and Pulmonary Exercises on Ventilatory Function in Patients with Restrictive Lung Diseases","2025-02-08",{"date":554,"type":33},"2025-02-11",{"date":556,"type":24},"2025-03-15",{"date":558,"type":24},"2025-07-15",{"name":39,"class":40},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":19,"minAge":567,"maxAge":74,"enrollmentInfo":568,"targetDuration":4,"studyType":132,"phases":569,"briefSummary":570,"conditions":571,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":41},"100579065","rab-32-gene-polymorphisms-as-a-prognostic-factor-in-leprosy-patients-100579065","NCT06819449","Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients","Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients and Its Relation to Multiple Drug Therapy: Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients of both sexes with positive slit skin smear for m.leprae .\n\nExclusion Criteria:\n\n* Contraindications to Multi drug therapy :\n* Patients with hypersensitivity to sulfa .\n* Patients with hypersensitivity to clofazimine or rifampcin.\n* pregnant or lactating women.","5 Years",{"count":291,"type":24},[134],"Mycobacterium leprae is a slow-growing bacillus that causes leprosy. the infection may take two to ten years to incubate. While the exact mechanism of infection transmission is unknown, direct bacillus absorption through the nasal or respiratory mucosa and aerosolized nasal secretions are the most common theories. The bacteria is subsequently transported by the bloodstream to the peripheral nerves, where it can result in tissue damage from painless burns and ulcers as well as irreparable nerve damage that results in a loss of protective feeling.",[572,573],"Leprosy","Mycobacterium Leprae Infection","2025-02-04",{"date":554,"type":33},{"date":577,"type":33},"2024-12-20",{"date":579,"type":24},"2025-12-20",{"name":39,"class":40},""]